21 CFR Part 11 Compliance in Clinical Trials: Complete Guide to Electronic Records & Signatures
Summary
Learn how 21 CFR Part 11 compliance applies to clinical trials, including electronic records, electronic signatures, audit trails, validation, and requirements for sponsors and CROs.- Author Company: Clinion eClinical Platform
- Author Name: Clinion eClinical Platform
- Author Website: https://www.clinion.com/
21 CFR Part 11 compliance defines how electronic records and electronic signatures can be used in FDA-regulated clinical trials and research environments. The regulation outlines requirements for system validation, audit trails, access controls, electronic signatures, and data integrity to help ensure electronic records remain accurate and traceable throughout the clinical trial lifecycle.
Overview of 21 CFR Part 11 Compliance in Clinical Trials
Clinical trials generate large volumes of data, and for many years, these records were managed on paper. But as organizations increasingly rely on electronic systems for clinical research, there is a growing need to ensure that digital records remain accurate and traceable.
This shift led to the introduction of 21 CFR Part 11 by the U.S. Food and Drug Administration, establishing requirements for the use of electronic records and electronic signatures in FDA-regulated environments.
Without proper controls, these systems can create risks related to unauthorized access, missing audit trails, and inconsistent records. 21 CFR Part 11 addresses these concerns through requirements for system validation, audit trails, electronic signatures, access controls, and data integrity.
What Is 21 CFR Part 11 Compliance?
21 CFR Part 11 is a regulation issued by the U.S. Food and Drug Administration that defines how electronic records and electronic signatures can be used in place of paper records and handwritten signatures in regulated environments.
The regulation applies to electronic records that are created, modified, maintained, archived, retrieved, or transmitted under FDA regulations. Its primary objective is to ensure that electronic records remain trustworthy and accurate throughout their lifecycle.
If an FDA predicate rule requires a record to be maintained, then the electronic version of that record typically falls under Part 11 requirements.
For example, Part 11 may apply to:
-
electronic case report forms (eCRFs)
-
informed consent records
-
laboratory data
-
trial management documentation
-
electronic signatures used for approvals or reviews
The regulation also establishes requirements for electronic signatures, ensuring that they are uniquely linked to individuals and cannot be reused or reassigned improperly.
Rather than focusing only on software functionality, 21 CFR Part 11 emphasizes accountability and data integrity across electronic records and signatures.
Read More: 21 CFR Part 11 Compliance in Clinical Trials: Complete Guide to Electronic Records & Signatures
